<DOC>
	<DOCNO>NCT02205476</DOCNO>
	<brief_summary>Study multicenter , two-part , open-label phase II study adult , evaluate safety long-term efficacy PF-06473871 one year surgical revision treatment PF-06473871 .</brief_summary>
	<brief_title>A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cicatrix , Hypertrophic</mesh_term>
	<criteria>Subjects previously randomize Pfizer clinical study B5301001 . Subjects must able tolerate 3 hour scar revision surgery sedation local anesthesia . Pregnant female subject ; breastfeed female subject ; male subject partner currently pregnant . Any previous history intolerable adverse reaction PF06473871 , serious adverse event attribute study drug withdrawn due AE prerequisite study B5301001 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>57 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>open-label</keyword>
	<keyword>safety</keyword>
	<keyword>hypertrophic scar revision surgery</keyword>
</DOC>